Jeffrey S Berger1, David L Brown. 1. Department of Medicine (Cardiovascular Medicine), Duke University, Durham, NC, USA.
Abstract
OBJECTIVES: We sought to evaluate the impact of GP IIb/IIIa receptor blockers on long-term mortality in patients undergoing PCI for AMI. BACKGROUND: Glycoprotein (GP) IIb/IIIa inhibitors are potent suppressors of platelet aggregation and when used during percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction (AMI) may improve short-term clinical outcomes, including survival. However, the impact of GP IIb/IIIa treatment during PCI for AMI on long-term survival is unknown. METHODS: Patients undergoing primary or rescue PCI for AMI within 24 hours of symptom onset with or without GP IIb/IIIa inhibitor treatment were identified from a multicenter PCI database. All cause mortality at a mean follow-up of 3 years was the primary end point. RESULTS: Of the 269 patients treated with primary or rescue PCI for AMI, 107 (40%) received a GP IIb/IIIa antagonist. Patients treated with GP inhibitors were more likely to present with or develop heart failure (13% vs. 6.2%, P = 0.052). Left ventricular ejection fraction was reduced in those treated with GP IIb/IIIa antagonists (44% vs. 48%, P = 0.051). The extent of coronary artery disease did not differ between groups. Stent use was 80% in both groups. Procedural success was high and did not differ between groups. In-hospital mortality was low and did not differ between groups. The mortality at a mean follow-up of 3 years was 1.9% among patients treated with a GP IIb/IIIa antagonist and 15% for those who were not treated (log-rank P = 0.0005). Treatment with a GP IIb/IIIa antagonist was independently associated with a significant reduction in the hazard of long-term mortality (Hazard Ratio, 0.159; 95% Confidence Interval, 0.034-0.729; P = 0.018). CONCLUSIONS: Treatment of patients undergoing PCI for AMI with GP IIb/IIIa antagonists appears to be associated with a profound reduction in late mortality.
OBJECTIVES: We sought to evaluate the impact of GP IIb/IIIa receptor blockers on long-term mortality in patients undergoing PCI for AMI. BACKGROUND: Glycoprotein (GP) IIb/IIIa inhibitors are potent suppressors of platelet aggregation and when used during percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction (AMI) may improve short-term clinical outcomes, including survival. However, the impact of GP IIb/IIIa treatment during PCI for AMI on long-term survival is unknown. METHODS:Patients undergoing primary or rescue PCI for AMI within 24 hours of symptom onset with or without GP IIb/IIIa inhibitor treatment were identified from a multicenter PCI database. All cause mortality at a mean follow-up of 3 years was the primary end point. RESULTS: Of the 269 patients treated with primary or rescue PCI for AMI, 107 (40%) received a GP IIb/IIIa antagonist. Patients treated with GP inhibitors were more likely to present with or develop heart failure (13% vs. 6.2%, P = 0.052). Left ventricular ejection fraction was reduced in those treated with GP IIb/IIIa antagonists (44% vs. 48%, P = 0.051). The extent of coronary artery disease did not differ between groups. Stent use was 80% in both groups. Procedural success was high and did not differ between groups. In-hospital mortality was low and did not differ between groups. The mortality at a mean follow-up of 3 years was 1.9% among patients treated with a GP IIb/IIIa antagonist and 15% for those who were not treated (log-rank P = 0.0005). Treatment with a GP IIb/IIIa antagonist was independently associated with a significant reduction in the hazard of long-term mortality (Hazard Ratio, 0.159; 95% Confidence Interval, 0.034-0.729; P = 0.018). CONCLUSIONS: Treatment of patients undergoing PCI for AMI with GP IIb/IIIa antagonists appears to be associated with a profound reduction in late mortality.
Authors: W D Weaver; R J Simes; A Betriu; C L Grines; F Zijlstra; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; M A DeWood; F Ribichini Journal: JAMA Date: 1997-12-17 Impact factor: 56.272
Authors: U Klinkhardt; C M Kirchmaier; D Westrup; H K Breddin; R Mahnel; J Graff; M Hild; S Harder Journal: Thromb Res Date: 2000-02-15 Impact factor: 3.944
Authors: Anna Sonia Petronio; Giuseppe Musumeci; Ugo Limbruno; Marco De Carlo; Roberto Baglini; Giovanni Paterni; Maria Grazia Delle Donne; Paolo Caravelli; Carmela Nardi; Mario Mariani Journal: Am Heart J Date: 2002-02 Impact factor: 4.749
Authors: S J Brener; L A Barr; J E Burchenal; S Katz; B S George; A A Jones; E D Cohen; P C Gainey; H J White; H B Cheek; J W Moses; D J Moliterno; M B Effron; E J Topol Journal: Circulation Date: 1998-08-25 Impact factor: 29.690
Authors: James E Tcheng; David E Kandzari; Cindy L Grines; David A Cox; Mark B Effron; Eulogio Garcia; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; Martin Fahy; Alexandra J Lansky; Roxana Mehran; Gregg W Stone Journal: Circulation Date: 2003-08-25 Impact factor: 29.690
Authors: C L Grines; K F Browne; J Marco; D Rothbaum; G W Stone; J O'Keefe; P Overlie; B Donohue; N Chelliah; G C Timmis Journal: N Engl J Med Date: 1993-03-11 Impact factor: 91.245
Authors: R R Azar; R G McKay; P D Thompson; J A Hirst; J F Mitchell; D B Fram; D D Waters; F J Kiernan Journal: J Am Coll Cardiol Date: 1998-12 Impact factor: 24.094